CAR T-Cell Therapy | Clinical

Immune System Plays Important Role in CAR T Cell Responses in Glioblastoma Models

April 16, 2021

Chimeric antigen receptor T-cell therapy mediates antigen-dependent and -independent antitumor effects, and CAR T-cell activation of host antitumor immunity is critical for productive solid tumor CAR T immunotherapy.

CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL

April 12, 2021

Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.

Further Promise for CAR T-cell Therapy Use in R/R MCL Observed with Liso-Cel

March 24, 2021

In an interview with Targeted Oncology, Maria Lia Palomba, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center, discussed the efficacy and safety of liso-cel in patients with R/R MCL as observed in the phase 1 TRANSCEND NHL 001 study.

Axi-cel Shows Better Outcomes When Given After Corticosteroids in R/R LBCL

March 24, 2021

Administering corticosteroids prior to chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel in adult patients with relapsed or refractory large B-cell lymphoma may positively impact the benefit/risk profile of axi-cel treatment.

Exploring the Potential of PSCA-Targeted CAR T-Cell Therapy to Treat mCRPC

March 23, 2021

Tanya B. Dorff, MD, a medical oncologist at the City of Hope Cancer Center, discusses the reasoning behind using PSCA-targeted chimeric antigen receptor T-cell therapy and the design of this early study in an interview with Targeted Oncology.

Research Ongoing for CAR T-Cell Therapy Axi-Cel in Lymphoma

March 17, 2021

Sairah Ahmed, MD, discusses the continued investigations of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy used in multiple types of lymphoma.

FDA Approves Axi-Cel for Relapsed/Refractory Follicular Lymphoma in Third-Line or Beyond

March 06, 2021

The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

KarMMa Data in Multiple Myeloma Published as FDA Considers Potential Ide-Cel Approval

March 03, 2021

Full results from the phase 2 KarMMa trial decabtagene vicleucel show the promise of idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Expert Anticipates a Changing Multiple Myeloma Paradigm With Ide-Cel

February 24, 2021

Yi Lin, MD, PhD, explains the potential impact the approval of idecabtagene vicleucel could bring to the multiple myeloma field.

Promising 5-Year Outcomes Shown With CAR T-Cell Therapy in R/R B-Cell Lymphoma

February 24, 2021

For the treatment of relapsed or refractory aggressive B-cell lymphomas, chimeric antigen receptor–modified T-cell therapy is becoming more widely used. Still, little is known about outcomes for patients who receive CAR-modified T-cell therapy beyond 2 years.